middl
east
respiratori
syndrom
coronaviru
merscov
highli
threaten
zoonot
pathogen
sinc
outbreak
similar
sarscov
merscov
belong
coronaviru
famili
induc
sever
respiratori
symptom
human
averag
case
fatal
rate
accord
world
health
organ
spike
protein
merscov
immunogen
induc
neutral
antibodi
thu
potenti
major
target
vaccin
develop
construct
chimer
viru
base
vesicular
stomat
viru
vsv
g
gene
replac
merscov
gene
protein
effici
incorpor
viral
envelop
mediat
cell
entri
bind
receptor
human
knockdown
clathrin
express
sirna
drastic
abrog
infect
vero
cell
furthermor
anim
studi
recombin
viru
induc
neutral
antibodi
cell
respons
rhesu
monkey
singl
intramuscular
intranas
immun
dose
find
indic
potenti
chimer
rapid
respons
vaccin
candid
emerg
merscov
diseas
middl
east
respiratori
syndrom
mer
sever
emerg
zoonot
diseas
sinc
initi
identif
june
saudi
arabia
mer
caus
infect
death
case
fatal
rate
countri
novemb
mer
caus
mer
coronaviru
merscov
belong
famili
coronavirida
genu
like
sarscov
belong
genu
merscov
zoonot
diseas
origin
bat
suggest
bat
like
natur
reservoir
merscov
annan
et
al
memish
et
al
wang
et
al
yang
et
al
studi
confirm
presenc
merscov
dromedari
arabian
peninsula
north
africa
hemida
et
al
kayali
peiri
reusken
et
al
dromedari
thought
main
reservoir
merscov
although
transmiss
merscov
camel
human
report
date
postul
primari
human
infect
could
result
close
contact
camel
shed
viru
azhar
et
al
note
major
mer
outbreak
south
korea
result
case
includ
death
major
case
health
care
worker
close
contact
infect
patient
korea
ministri
health
welfar
thu
develop
mer
vaccin
provid
rapid
immun
respons
highrisk
popul
health
care
worker
signific
import
public
health
coronaviru
spike
protein
immunogen
capabl
induc
protect
immun
coronaviru
infect
includ
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
yang
et
al
ying
et
al
inde
mvabas
dnabas
merscov
vaccin
design
protein
target
immunogen
proven
effect
anim
model
haagman
et
al
muthumani
et
al
song
et
al
volz
et
al
wang
et
al
howev
vaccin
strategi
requir
multipl
dose
elicit
desir
immun
respons
thu
may
ideal
emerg
vaccin
face
emerg
infecti
diseas
pandem
studi
demonstr
singledos
recombin
vesicular
stomat
viru
vsv
base
ebola
marburg
lassa
fever
vaccin
induc
rapid
immun
protect
anim
model
geisbert
et
al
marzi
et
al
marzi
et
al
exampl
larg
scale
clinic
trial
vsvvector
ebola
vaccin
rvsvzebov
conduct
west
africa
demonstr
singl
dose
rvsvzebov
immun
highli
safe
effect
human
henaorestrepo
et
al
report
vsvbase
chimer
recombin
viru
vsv
glycoprotein
g
gene
replac
merscov
gene
singledos
immun
either
intramuscular
intranas
rout
induc
highlevel
last
merscovspecif
neutral
antibodi
tcell
respons
rhesu
monkey
result
demonstr
therefor
potenti
candid
vaccin
merscov
previous
describ
pseudoviru
system
adapt
modifi
construct
chemic
synthes
merscov
gene
genbank
access
amplifi
pcr
flank
nhei
restrict
site
vsv
genestart
geneend
sequenc
introduc
pcr
product
sequenc
clone
nhei
site
egfp
gene
plasmid
contain
vsv
genom
cdna
without
g
gene
result
plasmid
name
two
mlui
site
flank
egfp
gene
construct
plasmid
achiev
mlui
digest
selflig
cotransfect
eukaryot
plasmid
express
vsv
n
p
l
protein
respect
cell
rescu
recombin
viru
h
posttransfect
supernat
harvest
clarifi
low
speed
centrifug
serial
passag
vero
cell
least
passag
obviou
green
fluoresc
cytopath
effect
cpe
observ
rescu
virus
name
respect
growth
kinet
recombin
virus
determin
respect
inocul
moi
onto
vero
cell
grow
plate
supernat
remov
interv
h
h
sampl
timepoint
titrat
vero
cell
use
indirect
immunofluoresc
stain
mous
anti
serum
tritclabel
goat
antimous
igg
primari
secondari
antibodi
titer
express
reciproc
highest
dilut
titer
fluoresc
form
unit
ffu
indirect
immunofluoresc
assay
vero
cell
infect
either
moi
h
postinfect
cell
fix
paraformaldehyd
cell
stain
mous
anti
serum
pcaggsmerss
immun
mous
serum
primari
antibodi
tritcconjug
goat
antimous
igg
secondari
antibodi
cell
nuclei
stain
hoechst
invitrogen
oregon
usa
stain
cell
analyz
leica
tc
laser
scan
confoc
microscop
leica
mannheim
germani
western
blot
assay
vero
cell
infect
either
moi
h
postinfect
cell
collect
lyse
cell
lysat
mix
protein
load
buffer
subject
sdspage
subsequ
electrotransf
nitrocellulos
membran
target
band
detect
mous
anti
serum
alexa
fluor
donkey
anti
mous
igg
invitrogen
oregon
usa
band
visual
odyssey
digit
fluoresc
imag
system
licor
nebraska
usa
cultur
harvest
infect
vero
cell
next
ml
supernat
clarifi
low
speed
centrifug
remov
cell
debri
subject
high
speed
centrifug
rpm
min
ml
supernat
care
taken
discard
remain
sampl
gentli
vortex
prepar
electron
microscopi
follow
previous
describ
protocol
ge
et
al
briefli
purifi
viru
bound
formvar
carbonco
nickel
grid
electron
microscopi
scienc
hatfield
pa
immunolabel
grid
block
pb
contain
globulinfre
bsa
sigmaaldrich
st
loui
mo
incub
mous
anti
antibodi
grid
wash
block
buffer
incub
gold
particleconjug
goat
antimous
igg
sigmaaldrich
st
loui
mo
final
wash
grid
neg
stain
phosphotungst
acid
subsequ
examin
model
transmiss
electron
microscop
hitachi
high
technolog
schaumburg
il
kv
imag
obtain
use
digit
camera
system
advanc
microscopi
techniqu
danver
knock
express
human
clathrin
gene
cell
use
ambion
valid
silenc
select
sirna
thermo
fisher
waltham
respect
target
specif
sequenc
clathrin
briefli
sirna
nm
per
well
target
clathrin
vsv
l
gene
posit
control
irrelev
sirna
neg
control
ambion
cat
prearray
cell
carrier
plate
perkin
elmer
waltham
respect
next
optimem
medium
invitrogen
oregon
usa
contain
lipofectamin
rnaimax
transfect
reagent
invitrogen
oregon
usa
mix
optimem
medium
contain
vero
cell
cellrnaimax
mix
ad
well
cell
incub
h
knockdown
gene
express
cell
infect
vsvegfp
moi
h
postinfect
h
vsvegfp
cell
fix
paraformaldehyd
stain
hoechst
invitrogen
oregon
usa
pb
h
stain
cell
imag
perkinelm
operetta
highcont
system
perkinelm
waltham
uninfect
cell
serv
refer
popul
background
fluoresc
fiftytwo
field
per
well
imag
magnif
columbu
softwar
perkinelm
waltham
use
automat
identifi
quantifi
green
fluoresc
cell
nuclei
infect
ratio
determin
accord
number
infect
versu
noninfect
cell
assay
independ
repeat
three
time
enzymelink
immunosorb
assay
elisa
determin
proteinspecif
igg
mous
monkey
serum
perform
describ
previous
kong
et
al
briefli
cell
seed
onto
two
well
plate
cell
infect
recombin
newcastl
diseas
viru
express
merscov
protein
liu
et
al
moi
h
postinfect
cell
pellet
collect
lyse
vigor
pipet
supernat
use
coat
antigen
antibodi
detect
use
hrplabel
goat
antimous
monkey
igg
southern
biotech
birmingham
al
standard
curv
gener
coat
elisa
plate
serial
dilut
purifi
mous
monkey
igg
southern
biotech
birmingham
al
known
concentr
linear
equat
obtain
base
standard
igg
concentr
od
valu
thu
concentr
mersspecif
igg
calcul
accord
linear
equat
base
od
valu
express
amount
igg
per
ml
serum
ngml
mous
monkey
serum
neutral
antibodi
level
determin
use
perform
neutral
assay
seriallydilut
serum
heat
inactiv
min
use
mix
dmem
contain
tcid
incub
h
incub
preincub
mixtur
ad
onto
vero
cell
triplic
well
plate
gfpexpress
cell
count
h
postinfect
fluoresc
microscop
viru
neutral
titer
vnt
express
reciproc
highest
dilut
serum
show
least
reduct
number
fluoresc
cell
compar
neg
control
monkey
immun
eight
old
male
rhesu
monkey
obtain
academi
militari
medic
scienc
beij
china
randomli
divid
two
group
group
intramuscularli
im
immun
ffu
prepar
describ
ml
medium
via
hind
limb
muscl
inject
anesthesia
group
intranas
immun
regimen
group
via
nostril
instil
anesthesia
monkey
hous
separ
cage
biosafeti
laboratori
equip
stabl
moistur
temperatur
monkey
fed
time
day
special
monkey
puf
diet
variou
fresh
fruit
adequ
drink
water
ten
femal
balbc
mice
vital
river
beij
china
intramuscularli
immun
ffu
ml
medium
via
hind
limb
muscl
inject
ten
control
mice
intramuscularli
inject
ml
medium
mice
monitor
daili
weight
chang
sign
ill
day
mice
given
booster
dose
week
first
dose
mice
blood
collect
week
prime
boost
immun
mice
sera
prepar
determin
mersspecif
igg
neutral
antibodi
anim
usag
strict
accord
guid
care
use
laboratori
anim
ministri
scienc
technolog
peopl
republ
china
protocol
approv
anim
research
ethic
committe
harbin
veterinari
research
institut
chines
academi
agricultur
scienc
enzymelink
immunospot
elispot
assay
perform
evalu
vaccineinduc
cell
respons
monkey
ten
day
immun
monkey
blood
drawn
lower
extrem
vein
anesthesia
peripher
blood
mononuclear
cell
pbmc
separ
monkey
lymphocyt
separ
buffer
tbd
scienc
tianjin
china
ensur
adequ
cell
number
monkey
pbmc
group
pool
synthet
overlap
peptid
pool
span
whole
merscov
protein
consist
peptid
amino
acid
overlap
design
cell
use
evalu
specif
cell
respons
briefli
millipor
ht
ha
steril
plate
millipor
usa
coat
purifi
mous
antihuman
bd
pharmingen
san
diego
ca
ml
pb
h
coat
solut
remov
ml
rpmi
medium
contain
dilut
peptid
ad
well
pbmc
ml
rpmi
medium
ad
well
mix
peptid
cell
cultur
peptid
h
induc
stimul
cell
remov
plate
vigor
wash
use
pbst
ml
biotinlabel
mous
anti
human
bd
pharmingen
san
diego
ca
ad
h
follow
ad
ml
hrpconjug
streptavidin
bd
pharmingen
san
diego
ca
h
final
wash
spot
develop
aec
substrat
bd
pharmingen
san
diego
ca
imag
spot
acquir
count
champspot
iii
elispot
reader
sage
creation
scienc
beij
china
data
analyz
excel
softwar
microsoft
redmond
wa
cutoff
threshold
set
spot
compar
neg
control
six
peptid
stimul
number
spot
select
inform
peptid
list
tabl
twoway
anova
bonferroni
multipl
comparison
test
use
statist
analysi
pvalu
twotail
consid
statist
signific
associ
probabl
less
construct
rescu
base
establish
vsv
indiana
strain
revers
genet
system
vsv
g
gene
replac
merscov
gene
egfp
gene
insert
gene
construct
shown
fig
express
protein
confirm
indirect
immunofluoresc
western
blot
fig
c
indirect
immunofluoresc
use
anti
protein
antibodi
confirm
surfac
express
protein
vero
cell
fig
egfp
express
confirm
infect
vero
cell
infect
cell
stain
vsv
g
monoclon
antibodi
shown
fig
uncleav
protein
faint
band
kda
cleav
protein
kda
cleav
protein
kda
millet
whittak
detect
purifi
virion
indic
incorpor
protein
viral
particl
show
similar
growth
kinet
vero
cell
peak
titer
reach
ffuml
h
postinfect
fig
recombin
virus
show
delay
growth
kinet
decreas
titer
compar
nativ
vsv
reach
ffuml
h
postinfect
genet
stabil
assess
serial
passag
viru
vero
cell
passag
express
gene
plu
egfp
gene
confirm
rtpcr
immunofluoresc
analys
data
shown
confirm
incorpor
protein
viral
particl
electron
immunoelectron
microscopi
perform
result
clearli
show
protein
incorpor
vsvmer
fig
long
arrow
vsv
g
protein
also
shown
vsv
vsvmer
particl
discrep
shape
compar
merscov
protein
fig
upper
panel
short
stealth
arrow
immunoelectron
microscopi
show
bind
goldlabel
secondari
antibodi
anti
antibodybound
protein
vsvmer
particl
fig
lower
panel
long
arrow
indic
protein
result
confirm
incorpor
protein
chimer
viral
particl
sinc
nativ
g
protein
replac
merscov
protein
execut
viral
attach
entri
virus
use
human
dipeptidyl
peptidas
entri
receptor
cell
express
human
nonpermiss
merscov
infect
transfect
cell
eukaryot
plasmid
encod
human
prior
infect
cell
shown
fig
cell
infect
cell
infect
viru
vero
cell
permiss
cell
merscov
result
demonstr
could
infect
vero
cell
form
larg
syncytia
fig
use
human
sirna
knockdown
express
vero
cell
advanc
infect
result
show
infect
significantli
reduc
fig
result
confirm
incorpor
function
protein
chimer
viral
particl
demonstr
use
human
cellular
receptor
infect
r
liu
et
al
antivir
research
well
demonstr
vsv
enter
cell
clathrindepend
endocyt
pathway
cureton
et
al
determin
whether
replac
vsv
g
merscov
alter
endocyt
pathway
clathrin
knockdown
viral
infect
assay
carri
result
show
signific
reduct
vsvegfp
infect
clathrin
knockdown
fig
fact
clathrin
knockdown
sever
influenc
infect
rate
vsvegfp
indic
infect
ratio
decreas
vsvegfp
versu
fig
ii
taken
togeth
result
indic
util
one
way
enter
cell
shown
syncytia
format
fig
clathrinmedi
endocytosi
fig
first
character
safeti
immunogen
balbc
mice
mice
intramuscularli
inocul
ffu
monitor
daili
detect
bodi
weight
chang
sign
ill
death
result
show
mice
healthi
exhibit
untoward
clinic
sign
bodi
weight
gain
similar
experiment
pb
control
group
mice
two
week
postinocul
fig
evalu
r
liu
et
al
antivir
research
humor
immun
respons
proteinspecif
igg
neutral
antibodi
result
show
high
level
specif
igg
detect
initi
inocul
measur
day
specif
igg
significantli
boost
second
dose
day
measur
day
p
fig
mer
neutral
antibodi
also
detect
first
dose
significantli
boost
second
dose
p
fig
due
fact
mice
infect
express
human
result
demonstr
potenti
serv
inactiv
mer
vaccin
investig
immunogen
vaccin
nonhuman
primat
rhesu
monkey
intramuscularli
intranas
immun
ffu
specif
humor
cell
respons
evalu
shown
fig
singl
dose
immun
induc
signific
mer
protein
specif
igg
monkey
vaccin
via
intramuscular
im
intranas
rout
igg
detect
post
immun
remain
elev
least
day
peak
igg
level
appear
day
statist
differ
exist
imand
inimmun
monkey
timepoint
fig
monkey
mer
protein
neutral
antibodi
induc
im
immun
detect
day
post
immun
reach
peak
level
day
fig
neutral
antibodi
titer
im
group
significantli
higher
group
timepoint
fig
indic
im
rout
might
better
facilit
product
neutral
antibodi
case
immun
monkey
evalu
cell
respons
immun
monkey
elispot
overlap
peptid
pool
consist
peptid
span
mer
protein
use
stimul
pbmc
peptid
amino
acid
overlap
design
preferenti
stimul
cell
secret
cell
count
analyz
shown
fig
imand
inimmun
monkey
produc
activ
cell
respons
specif
protein
peptid
stimul
peptid
select
domin
peptid
induc
highest
level
secret
spotswel
averag
compar
respons
pmaiono
posit
control
spotswel
averag
hypothes
peptid
potenti
contain
monkey
proteinspecif
pbmc
immun
monkey
test
merscov
peptidespecif
cell
respons
elispot
protein
overlap
peptid
pool
contain
peptid
design
cell
use
stimul
monkey
pbmc
exvivo
elispot
assay
perform
determin
activ
cell
six
peptid
yield
spot
select
present
statist
differ
observ
peptid
im
group
r
liu
et
al
antivir
research
cell
epitop
statist
signific
observ
imand
inimmun
group
select
peptid
fig
studi
success
construct
vsvbase
recombin
chimer
viru
bear
merscov
protein
new
membran
glycoprotein
replac
g
protein
chimer
viru
replic
compet
permiss
cell
util
protein
sole
membran
anchor
glycoprotein
recogn
human
receptor
complet
attach
cell
entri
demonstr
singledos
immun
either
intramuscular
intranas
rout
induc
highlevel
last
merscovspecif
neutral
antibodi
cell
respons
rhesu
monkey
date
sever
type
mer
vaccin
report
mainli
includ
live
attenu
vaccin
dna
vaccin
subunit
vaccin
recombin
vector
vaccin
measl
viru
mva
adenoviru
thu
far
dna
vaccin
recombin
vector
vaccin
shown
efficaci
experiment
anim
modjarrad
et
al
note
mva
vector
vaccin
highli
immunogen
could
significantli
reduc
merscov
excret
dromedari
camel
haagman
et
al
measl
viru
vector
vaccin
also
highli
immunogen
protect
human
mice
malczyk
et
al
result
clearli
demonstr
great
potenti
livevector
vaccin
howev
vaccin
requir
multipl
dose
gener
desir
immun
respons
thu
ideal
emerg
necessit
rapid
immun
respons
emerg
infecti
diseas
like
mer
contrast
singl
dose
immun
would
suffic
induc
ideal
immun
respons
previou
studi
success
gener
vsv
pseudoviru
bear
sarscov
protein
neutral
assay
cellentri
assay
replac
vsv
g
gene
sarscov
gene
success
rescu
recombin
chimer
viru
use
vsv
revers
genet
system
unpublish
work
thu
present
studi
construct
deploy
strategi
rescu
viru
manifest
delay
growth
kinet
decreas
peak
titer
compar
nativ
vector
viru
fig
protein
therefor
sole
viral
membran
anchor
glycoprotein
instead
vsv
g
protein
critic
receptor
bind
viral
entri
furthermor
incorpor
protein
alter
morpholog
viru
bullet
shape
virion
fig
obvious
alter
tropism
entri
viru
recombin
viru
requir
human
cellular
receptor
fig
b
protein
also
influenc
entri
mode
recombin
viru
shown
fig
signific
syncytia
format
observ
vero
cell
vsvinfect
cell
observ
indic
viru
util
direct
membran
fusion
enter
cell
accord
previou
studi
show
merscov
could
enter
cell
partial
via
direct
membran
fusion
qian
et
al
result
demonstr
clathrin
play
import
role
entri
shown
fig
knock
clathrin
express
sirna
vero
cell
larg
reduc
infect
rate
result
indic
recombin
viru
could
enter
cell
via
clathrinmedi
endocytosi
agreement
studi
show
merscov
could
enter
cell
either
direct
membran
fusion
clathrinmedi
endocytosi
de
wit
et
al
vivo
result
demonstr
efficaci
immunogen
mice
rhesu
monkey
theoret
balbc
mice
infect
due
lack
human
thu
recombin
viru
similar
inactiv
vaccin
viruslik
particl
vaccin
mice
result
show
induc
robust
humor
immun
respons
mice
twodos
im
immun
importantli
result
demonstr
singl
im
inocul
dose
could
induc
effect
humor
cell
respons
rhesu
monkey
quantit
elisa
result
show
recombin
viru
induc
high
level
protein
specif
igg
group
statist
differ
exist
im
group
timepoint
howev
result
neutral
antibodi
quit
differ
im
group
demonstr
significantli
higher
level
neutral
antibodi
group
timepoint
im
inocul
effect
gener
neutral
antibodi
rout
level
serum
neutral
antibodi
follow
inocul
significantli
higher
baselin
trivial
therefor
suggest
futur
applic
singl
dose
vaccin
given
via
im
rout
ensur
solid
immun
present
studi
unabl
carri
viral
neutral
assay
use
merscov
due
unavail
merscov
per
se
thu
use
mimic
merscov
determin
neutral
titer
method
similar
use
protein
bear
pseudovirus
lentivir
particl
grehan
et
al
jaum
et
al
replic
compet
stabl
suitabl
neutral
antibodi
assay
date
sever
merscov
anim
model
report
includ
rhesu
macaqu
de
wit
et
al
munster
et
al
yao
et
al
common
marmoset
falzarano
et
al
transgen
mice
agraw
et
al
pascal
et
al
adenoviru
transduc
mice
zhao
et
al
due
unavail
merscov
monkey
challeng
studi
could
undertaken
current
studi
set
undertaken
futur
studi
consid
neutral
antibodi
level
gener
correl
neutral
antibodi
protect
specul
vaccin
confer
protect
merscov
studi
support
nation
key
technolog
r
program
